menu
    • menu

    Company profile for Sarepta Therapeutics

    NEW Drugs in Dev.: 20
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our vision is to transform how the world approaches the treatment of serious and life-threatening diseases by unlocking the potential of RNA-based technologies. Recognizing the complexity of this goal, we focus on rare neuromuscular diseases which represent tremendous unmet needs—areas in which new therapies have the potential to make dramatic improvements in the lives of patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sarepta TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    215 First Street Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sarepta.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sarepta-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/sarepta

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sarepta Reports 2025 Net Product Revenues For Q4 And Full Year
    Sarepta Reports 2025 Net Product Revenues For Q4 And Full Year

    12 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260112936766/en/Sarepta-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2025-Net-Product-Revenues

    BUSINESSWIRE
    12 Jan 2026
    Share Share
    Sarepta Submits CTA for SRP-1005 in Huntington's Disease
    Sarepta Submits CTA for SRP-1005 in Huntington's Disease

    07 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260107174240/en/Sarepta-Therapeutics-Announces-Submission-of-Clinical-Trial-Application-for-SRP-1005-its-Investigational-Treatment-for-Huntingtons-Disease

    BUSINESSWIRE
    07 Jan 2026
    Share Share
    Sarepta Presents at 44th J.P. Morgan Healthcare Conference
    Sarepta Presents at 44th J.P. Morgan Healthcare Conference

    05 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260105003354/en/Sarepta-Therapeutics-to-Present-at-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

    BUSINESSWIRE
    05 Jan 2026
    Share Share
    Sarepta Awards Inducements Under Nasdaq Rule 5635(c)(4)
    Sarepta Awards Inducements Under Nasdaq Rule 5635(c)(4)

    31 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251231461456/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    31 Dec 2025
    Share Share
    Sarepta Refinances $291M 1.25% Convertible Notes
    Sarepta Refinances $291M 1.25% Convertible Notes

    11 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251211507407/en/Sarepta-Therapeutics-Announces-Refinancing-of-Approximately-%24291-Million-of-1.25-Convertible-Senior-Notes-due-2027

    BUSINESSWIRE
    11 Dec 2025
    Share Share
    Dyne readies FDA push after DMD exon 51 med excels in trial
    Dyne readies FDA push after DMD exon 51 med excels in trial

    08 Dec 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/dyne-readies-fda-push-after-dmd-exon-51-med-excels-trial

    FIERCE BIOTECH
    08 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Contact Sarepta Therapeutics and get a quotation

    Sarepta Therapeutics is a supplier offers 2 products (APIs, Excipients or Intermediates).

    Find a price of SRP-2001 DRUG SUBSTANCE bulk offered by Sarepta Therapeutics

    Find a price of AVI 4126 bulk offered by Sarepta Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search